The European Commission has granted EU marketing authorisation for a two-dose schedule of Gardasil in children aged 0-6 months and 9-13 years.
A spokeswoman for manufacturer Sanofi Pasteur MSD said the new schedule 'could help to extend HPV vaccine coverage and increase uptake'.
It follows a positive decision by the European Medicines Agency in February, after research found a two-dose schedule is just as effective as the current three-dose schedule used in the NHS programme.
The UK's Joint Committee on Vaccination and Immunisation (JCVI) has since considered the evidence and recommended the NHS switch to a two-dose plan, saying the change could make the programme more cost effective.
Public Health England (PHE) told GP the change will be made 'as soon as practically possible'.